[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUE066137T2 - A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére - Google Patents

A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére

Info

Publication number
HUE066137T2
HUE066137T2 HUE22178736A HUE22178736A HUE066137T2 HU E066137 T2 HUE066137 T2 HU E066137T2 HU E22178736 A HUE22178736 A HU E22178736A HU E22178736 A HUE22178736 A HU E22178736A HU E066137 T2 HUE066137 T2 HU E066137T2
Authority
HU
Hungary
Prior art keywords
psma
treatment
agents
specific membrane
membrane antigen
Prior art date
Application number
HUE22178736A
Other languages
English (en)
Inventor
Matthias Eder
Klaus Kopka
Martin Schäfer
Ulrike Bauder-Wuest
Uwe Haberkorn
Martina Benesova
Walter Mier
Hans-Christian Kliem
Clemens Kratochwil
Michael Eisenhut
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51903864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE066137(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP20130004991 external-priority patent/EP2862857A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUE066137T2 publication Critical patent/HUE066137T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nuclear Medicine (AREA)
HUE22178736A 2013-10-18 2014-10-17 A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére HUE066137T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20130004991 EP2862857A1 (en) 2013-10-18 2013-10-18 Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP14175612 2014-07-03

Publications (1)

Publication Number Publication Date
HUE066137T2 true HUE066137T2 (hu) 2024-07-28

Family

ID=51903864

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE22178736A HUE066137T2 (hu) 2013-10-18 2014-10-17 A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére
HUS2400024C HUS2400024I1 (hu) 2013-10-18 2024-07-10 A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS2400024C HUS2400024I1 (hu) 2013-10-18 2024-07-10 A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére

Country Status (34)

Country Link
US (8) US20160228587A1 (hu)
EP (6) EP4374924A3 (hu)
JP (7) JP2016535013A (hu)
KR (3) KR102210931B1 (hu)
CN (2) CN109053616B (hu)
AU (3) AU2014336638C1 (hu)
CA (1) CA2924360C (hu)
CL (1) CL2016000883A1 (hu)
DE (2) DE202014011593U1 (hu)
DK (1) DK4095130T3 (hu)
EA (1) EA037778B1 (hu)
ES (1) ES2977715T3 (hu)
FI (2) FI4095130T3 (hu)
FR (1) FR24C1028I1 (hu)
GE (4) GEP20217330B (hu)
HK (1) HK1221711A1 (hu)
HR (1) HRP20240398T1 (hu)
HU (2) HUE066137T2 (hu)
IL (2) IL245113B (hu)
LT (1) LT4095130T (hu)
MX (3) MX2016005013A (hu)
MY (2) MY194484A (hu)
NL (1) NL301281I2 (hu)
NZ (1) NZ718812A (hu)
PE (2) PE20211760A1 (hu)
PH (1) PH12016500656A1 (hu)
PL (1) PL4095130T3 (hu)
RS (1) RS65324B1 (hu)
SA (1) SA516370842B1 (hu)
SG (1) SG11201602249RA (hu)
SI (1) SI4095130T1 (hu)
TN (1) TN2016000137A1 (hu)
WO (1) WO2015055318A1 (hu)
ZA (2) ZA201603380B (hu)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2847275T3 (es) 2006-11-08 2021-08-02 Molecular Insight Pharm Inc Heterodímeros de ácido glutámico
PT2187965T (pt) 2007-08-17 2020-01-17 Purdue Research Foundation Conjugados ligando-ligante de ligação a psma e métodos para utilização
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EA201890915A1 (ru) 2012-11-15 2018-09-28 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
HRP20240398T1 (hr) 2013-10-18 2024-06-07 Novartis Ag Označeni inhibitori prostata specifičnog membranskog antigena (psma), njihova upotreba kao sredstava za snimanje i farmaceutska sredstva za liječenje raka prostate
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
EP3337520A1 (en) * 2015-08-20 2018-06-27 Universität zu Köln Pain tracking by pet-imaging (pain-trap)
BR112018005899A2 (pt) * 2015-09-30 2018-10-16 Deutsches Krebsforschungszentrum composto e composição farmacêutica
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
HUE065327T2 (hu) * 2016-03-22 2024-05-28 Univ Johns Hopkins Prosztata-fajlagos membrán antigénhez célzott nagy affinitású szerek prosztatarák endoradioterápiájához
WO2018108287A1 (en) * 2016-12-15 2018-06-21 The European Atomic Energy Community (Euratom), Represented By The European Commission Treatment of pmsa expressing cancers
US11285227B2 (en) 2017-04-05 2022-03-29 Cornell University Trifunctional constructs with tunablepharmacokinetics useful in imaging and anti-tumor therapies
JP7373998B2 (ja) 2017-05-02 2023-11-06 コーネル・ユニバーシティー 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬
CN111263747B (zh) 2017-05-05 2023-10-27 探针技术开发及商业化中心 双官能螯合物的药代动力学增强及其用途
KR20200004861A (ko) 2017-05-05 2020-01-14 퓨전 파마슈티칼즈 인크. Igf-1r 모노클로날 항체 및 그의 용도
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
AU2018274184B2 (en) 2017-05-24 2024-06-13 ITM Isotope Technologies Munich SE Novel PSMA-binding agents and uses thereof
WO2018233798A1 (en) 2017-06-20 2018-12-27 ITM Isotopen Technologien München AG NOVEL PSMA BINDING AGENTS AND USE THEREOF
JP2020522506A (ja) * 2017-05-30 2020-07-30 ザ・ジョンズ・ホプキンス・ユニバーシティ 前立腺がんの内部放射線療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤
US11560426B2 (en) 2017-06-09 2023-01-24 Avencell Europe Gmbh Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders
CN207184660U (zh) 2017-09-15 2018-04-03 南昌欧菲光电技术有限公司 摄像模组
CN109510921A (zh) 2017-09-15 2019-03-22 南昌欧菲光电技术有限公司 摄像模组
CN109510925A (zh) 2017-09-15 2019-03-22 南昌欧菲光电技术有限公司 摄像模组
AU2018352731B2 (en) * 2017-10-22 2023-10-05 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
EP3710068A1 (en) * 2017-11-13 2020-09-23 Deutsches Krebsforschungszentrum A double-labeled probe for molecular imaging and use thereof
JP7324763B2 (ja) 2017-11-21 2023-08-10 ドイチェス クレブスフォルシュンクスツェントルム 分子イメージングのための二重標識プローブ及びその使用
KR20200097690A (ko) * 2017-12-11 2020-08-19 테크니쉐 우니베르지테트 뮌헨 영상화 및 내부 방사선 요법을 위한 psma 리간드
BR112020011789A2 (pt) * 2017-12-13 2020-11-24 Sciencons AS complexo que compreende um composto de alvejamento de psma ligado a um radionuclídeo de chumbo ou tório
WO2019157037A1 (en) * 2018-02-06 2019-08-15 The Johns Hopkins University Psma targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
MX2018003175A (es) 2018-03-14 2019-09-16 Instituto Nac De Investigaciones Nucleares 177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana.
EA202092333A1 (ru) 2018-03-30 2021-01-21 Фьючеркем Ко., Лтд. Псма-таргетные радиофармацевтические средства для диагностики и лечения рака простаты
CN112368024A (zh) * 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
CN113166087B (zh) * 2018-09-21 2024-05-10 恩多塞特公司 屏蔽剂及其用途
WO2020061458A1 (en) * 2018-09-21 2020-03-26 Endocyte, Inc. Methods of treating cancer
BR112021005931A2 (pt) 2018-09-28 2021-06-29 Universität Heidelberg composto, complexo e composição farmacêutica
DE102018126558A1 (de) 2018-10-24 2020-04-30 Helmholtz-Zentrum Dresden - Rossendorf E.V. Markierungsvorläufer mit Quadratsäure-Kopplung
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
CA3118223A1 (en) * 2018-12-18 2020-06-25 Provincial Health Services Authority Dual mode 18f-labelled theranostic compounds and uses thereof
JP7528100B2 (ja) 2019-01-30 2024-08-05 テクニシェ ユニバーシタット ミュンヘン Ｐｓｍａ結合デュアルモード放射性トレーサーおよび療法
CN113747927B (zh) 2019-02-14 2024-10-18 德国癌症研究中心 包含淀粉酶可切割接头的前列腺特异性膜抗原(psma)配体
US20220118121A1 (en) 2019-02-14 2022-04-21 Ruprecht-Karls-Universität Heidelberg Prostate specific membrane antigen (psma) ligands with improved tissue specificity
US11396535B2 (en) 2019-03-01 2022-07-26 Provincial Health Services Authority Cyclic peptide analogs of melanocortin and amanitin and methods of making such
PL239934B1 (pl) 2019-04-12 2022-01-31 Narodowe Centrum Badan Jadrowych Osrodek Radioizotopow Polatom Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty
CA3136979A1 (en) * 2019-04-17 2020-10-22 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer
KR20220004125A (ko) * 2019-04-26 2022-01-11 파이브 일레븐 파마 인크. 진단제 및 방사성핵종 치료제로서의 전립선-특이적 막 항원 (psma) 억제제
EP3972627A4 (en) * 2019-05-20 2023-06-21 Endocyte, Inc. METHODS FOR PRODUCTION OF PSMA CONJUGATES
CA3144094A1 (en) 2019-06-21 2020-12-24 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
CN114341118A (zh) * 2019-07-02 2022-04-12 先进加速器应用意大利公司 前列腺特异性膜抗原(psma)配体及其用途
AR119479A1 (es) 2019-07-25 2021-12-22 Bayer As Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer
DE102019135564B4 (de) 2019-12-20 2022-05-19 Johannes-Gutenberg-Universität Mainz Verbindung für Smart-Drug-Delivery und pharmazeutisches Kit für duale nuklearmedizinisch-cytotoxische Theranostik
CN113350531A (zh) * 2020-03-02 2021-09-07 上海核力星医药科技有限公司 前列腺特异性膜抗原结合配体偶联物及其应用
WO2021202376A1 (en) 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
WO2021225760A1 (en) * 2020-05-06 2021-11-11 Cornell University Copper-containing theragnostic compounds and methods of use
EP3919082A1 (en) * 2020-06-04 2021-12-08 Rigshospitalet Psma targeting urea-based ligands for prostate cancer radiotherapy and imaging
US11129912B1 (en) 2020-07-13 2021-09-28 POINT Biopharma Inc. Radiopharmaceutical and methods
CA3185565A1 (en) 2020-07-13 2022-01-20 Joe Mccann Radiopharmaceutical and methods
CN112062695B (zh) * 2020-08-14 2021-04-06 北京大学第一医院 一种前列腺特异性膜抗原靶向抑制剂及应用和探针
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
CN112321673B (zh) * 2020-11-04 2022-09-20 北京市肿瘤防治研究所 一种前列腺特异性膜抗原靶向抑制剂及应用和探针
WO2022096103A1 (en) 2020-11-05 2022-05-12 ITM Isotopen Technologien München AG Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
CN116438190A (zh) * 2020-11-19 2023-07-14 诺华股份有限公司 前列腺特异性膜抗原(psma)配体的合成
WO2022111800A1 (en) 2020-11-25 2022-06-02 Itm Solucin Gmbh Stable formulations for radionuclide complexes
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
DE102021101216A1 (de) 2021-01-21 2022-07-21 Johannes Gutenberg-Universität Mainz, Körperschaft des öffentlichen Rechts Markierungsvorläufer und Radiotracer zur nuklearmedizinischen Diagnose und Therapie von Prostatakrebs induzierten Knochenmetastasen
CN112851637B (zh) * 2021-01-22 2022-11-18 北京瑞达福明科技有限公司 一种psma抑制剂、化合物及其制备方法与用途
CA3208778A1 (en) 2021-01-22 2022-07-28 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof
CN112898270B (zh) * 2021-01-22 2023-03-21 周彤 一种诊疗一体的psma抑制剂、化合物及其制备方法与用途
EP4288116A1 (en) 2021-02-08 2023-12-13 Stichting Radboud universitair medisch centrum Psma-targeting ligands for multimodal applications
WO2022226326A1 (en) * 2021-04-23 2022-10-27 Wisconsin Alumni Research Foundation Psma-targeting ligands with optimal properties for imaging and therapy
WO2022246183A1 (en) * 2021-05-21 2022-11-24 Northstar Medical Technologies Llc Trivalent radioisotope bio-targeted radiopharmaceutical, methods of preparation and use
CN113372285B (zh) * 2021-05-28 2024-06-18 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其放射性核素标记物及制法和应用
DE102021114711B4 (de) 2021-06-08 2023-11-02 Medianezia GmbH Trislinker-konjugierte dimere Markierungsvorläufer und daraus abgeleitete Radiotracer
MX2024001424A (es) 2021-07-30 2024-05-20 Univ Osaka Compuesto radiomarcado y uso del mismo.
WO2023030434A1 (zh) * 2021-09-01 2023-03-09 天津恒瑞医药有限公司 前列腺特异性膜抗原的抑制剂及其医药用途
CN115745903B (zh) * 2021-09-03 2024-07-23 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
CN114014843B (zh) * 2021-11-17 2022-09-20 北京大学第一医院 一种psma靶向核素/荧光双模态配体和分子探针与应用
WO2023143612A1 (zh) * 2022-01-30 2023-08-03 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
WO2023208928A1 (en) 2022-04-26 2023-11-02 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Dosage of psma-ligands for fluorescence based detection of cancerous tissue
WO2023222681A1 (en) 2022-05-17 2023-11-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Prostate specific membrane antigen (psma) ligands with improved renal clearance
AU2023270705A1 (en) 2022-05-17 2024-11-07 Albert-Ludwigs-Universität Freiburg Prostate specific membrane antigen (psma) ligands
WO2023222680A1 (en) 2022-05-17 2023-11-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Prostate specific membrane antigen (psma) ligands
WO2023222679A1 (en) 2022-05-17 2023-11-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Prostate specific membrane antigen (psma) ligands
CN114874122A (zh) * 2022-05-31 2022-08-09 南京航空航天大学 一种新的小分子抑制剂及其制备方法和应用
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
WO2024150132A1 (en) 2023-01-10 2024-07-18 Sun Pharma Advanced Research Company Limited Ligand-drug conjugates
US20240316226A1 (en) * 2023-03-24 2024-09-26 Jubilant Draximage Inc. Radiopharmaceutical conjugate compound for diagnosis and/or therapeutic uses thereof

Family Cites Families (343)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713249A (en) 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
EP0116208B1 (en) 1982-12-07 1988-03-30 Kyowa Hakko Kogyo Co., Ltd. Mitomycin analogues
JPS60255789A (ja) 1984-06-01 1985-12-17 Kyowa Hakko Kogyo Co Ltd マイトマイシン誘導体，その製造法および抗腫瘍剤
US5266333A (en) 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
WO1988001622A1 (en) 1986-08-29 1988-03-10 Kyowa Hakko Kogyo Kabusiki Kaisha Mitomycin derivatives
USH806H (en) 1987-07-16 1990-08-07 Fmc Corporation Herbicidal clomazone compositions and methods of use tolerant to corn and other crops
CA2044590A1 (en) 1989-11-13 1991-05-14 Marc D. Better Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
AU653565B2 (en) 1990-12-21 1994-10-06 Nikken Corporation Raw sewage disposal apparatus and prefab for accomodating the same
US6342491B1 (en) 1991-05-21 2002-01-29 American Home Products Corporation Method of treating estrogen receptor positive carcinoma with 17 α-dihydroequilin
US6291196B1 (en) 1992-01-31 2001-09-18 Research Corporation Technologies, Inc. Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
US7070782B1 (en) 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5674977A (en) 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
GB9314623D0 (en) 1993-07-14 1993-08-25 Nordion Int Inc Localization and therapy with agents directed against prostate specific antigen in breast cancer
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
JP3538221B2 (ja) 1993-11-19 2004-06-14 富士写真フイルム株式会社 定着濃厚液およびそれを用いたハロゲン化銀写真感光材料の処理方法
US5417982A (en) 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6946133B1 (en) 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
CN1108824C (zh) 1996-04-01 2003-05-21 Epix医学公司 生物活化的诊断成像造影剂
US5962237A (en) 1996-04-05 1999-10-05 The Johns Hopkins University School Of Medicine Method of enriching rare cells
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US5863536A (en) 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US6054444A (en) 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US5998362A (en) 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6548260B1 (en) 1997-01-21 2003-04-15 Bayer Corporation Detection of PSA-α2-macroglobulin complex in a biological fluid
ES2324503T3 (es) 1997-04-10 2009-08-07 Stichting Katholieke Universiteit University Medical Centre Nijmegen Pca3, genes pca3 y metodos de uso.
US6265540B1 (en) 1997-05-19 2001-07-24 The Johns Hopkins University School Of Medicine Tissue specific prodrug
US6504014B1 (en) 1997-05-19 2003-01-07 The John Hopkins University Tissue specific prodrug
US6127333A (en) 1997-07-10 2000-10-03 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20020115596A1 (en) 1997-10-27 2002-08-22 Merk & Co., Inc. Conjugates useful in the treatment of prostate cancer
KR100580137B1 (ko) 1997-12-02 2006-05-16 머크 앤드 캄파니 인코포레이티드 전립선 암 치료에 유용한 접합체 및 이를 포함하는 약제학적 조성물
US20040081659A1 (en) 1997-12-02 2004-04-29 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
ZA9810974B (en) 1997-12-02 1999-06-03 Merck & Co Inc Conjugates useful in the treatment of prostate cancer
AU2896399A (en) 1998-03-03 1999-09-20 Exact Sciences Corporation Purification and detection processes using reversible affinity electrophoresis
US20020103136A1 (en) 1998-03-05 2002-08-01 Dong-Mei Feng Conjugates useful in the treatment of prostate cancer
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
FR2778820B1 (fr) 1998-05-20 2000-07-28 Rhone Poulenc Agrochimie Melanges herbicides a base d'aclonifen et de clomazone
ES2329851T3 (es) 1998-06-01 2009-12-01 Agensys, Inc. Nuevos antigenos transmembranables expresados en canceres humano y utilizacion de los mismos.
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6518033B1 (en) 1998-08-05 2003-02-11 The Research Foundation Of State University Of New York Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment
US20070020327A1 (en) 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US20030207808A1 (en) 1999-02-18 2003-11-06 Kinneret Savitzky Novel nucleic acid and amino acid sequences
WO2000059930A1 (en) 1999-04-05 2000-10-12 Merck & Co., Inc. A method of treating cancer
EP1177200B1 (en) 1999-04-28 2005-06-22 Georgetown University Ligands for metabotropic glutamate receptors
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
AUPQ014799A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
US20040146516A1 (en) 1999-06-17 2004-07-29 Utah Ventures Ii L.P. Lumen-exposed molecules and methods for targeted delivery
AU781925B2 (en) 1999-07-13 2005-06-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The T-cell receptor gamma alternate reading frame protein, (TARP) and uses thereof
US7060284B1 (en) 1999-08-03 2006-06-13 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6692724B1 (en) 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
EP1228089A2 (en) 1999-10-27 2002-08-07 Merck & Co., Inc. Salt form of a conjugate useful in the treatment of prostate cancer
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
CA2391534A1 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
EP1267918A4 (en) 2000-03-31 2007-06-27 Purdue Research Foundation TREATMENT PROCEDURE USING LIGAND IMMUNOGENIC CONJUGATES
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
AU2002224401B2 (en) 2000-10-16 2007-12-06 Gilead Sciences, Inc. Nucleic acid ligands to the prostate specific membrane antigen
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
AU2002239403A1 (en) 2000-12-01 2002-06-11 The Johns Hopkins University Tissue specific prodrugs
EP1390081A2 (en) 2001-01-08 2004-02-25 Neorx Corporation Therapeutic and diagnostic compounds, compositions, and methods
US6875886B2 (en) 2001-02-07 2005-04-05 Beth Israel Deaconess Medical Center, Inc. Modified PSMA ligands and uses related thereto
WO2002074345A2 (en) 2001-03-16 2002-09-26 Johns Hopkins University School Of Medicine Immune modulation by transduced hematopoietic stem cells expressing antigens and antigen-presenting cell regulatory molecules
CA2441386C (en) 2001-03-21 2010-12-21 L. Molteni E C. Dei Fratelli Alitti Societa Di Esercizio S.P.A. Metal substituted non centrosymmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic
CN102643333B (zh) 2001-03-29 2019-04-23 药物协和公司 用于治疗组织炎症和癌变的鸟苷酸环化酶受体激动剂
ATE427948T1 (de) 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
JP4868698B2 (ja) 2001-05-02 2012-02-01 パーデュー・リサーチ・ファウンデーション マクロファージが仲介する疾患の治療および診断
US20040092890A1 (en) 2001-05-10 2004-05-13 Ash Stephen R. Catheter lock solution including a photo-oxidant
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
CA2447695C (en) 2001-06-01 2015-02-24 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US20040018203A1 (en) 2001-06-08 2004-01-29 Ira Pastan Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
WO2003000117A2 (en) 2001-06-21 2003-01-03 Glycotech Corporation Detection and treatment of prostate cancer
EP1409017A4 (en) 2001-06-25 2006-05-24 Drug Innovation & Design Inc CELL TARGETING INVOLVING THE RECONNAISSANCE OF EXPONENTIAL FORMS, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS
US7755757B2 (en) 2007-02-14 2010-07-13 Chemimage Corporation Distinguishing between renal oncocytoma and chromophobe renal cell carcinoma using raman molecular imaging
US6596755B2 (en) 2001-07-02 2003-07-22 Dabur Research Foundation Oral formulation of methylglyoxal and its imino acid conjugates for human use
WO2003004469A1 (en) 2001-07-02 2003-01-16 Dabur Research Foundation Anticancer activity of imino acid conjugates of methylglyoxal
US7893223B2 (en) 2001-07-17 2011-02-22 Bracco Imaging S.P.A. Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy
ES2542888T3 (es) 2001-08-24 2015-08-12 Uvic Industry Partnerships Inc. Proaerolisina que contiene secuencias de activación de proteasa y métodos de uso para el tratamiento del cáncer de próstata
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
MXPA03012022A (es) 2001-09-20 2005-07-01 Cornell Res Foundation Inc Metodos y composiciones para tratar o prevenir padecimientos de la piel, utilizando agentes de enlace especificos para el antigeno de membrana especifico de prostata.
US20030232760A1 (en) 2001-09-21 2003-12-18 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
JP2005523878A (ja) 2001-09-28 2005-08-11 パーデュー・リサーチ・ファウンデーション リガンド・免疫原物質複合体を用いた処置方法
US20030215456A1 (en) 2001-10-02 2003-11-20 Sui-Long Yao Method of treating cancer
US20030133927A1 (en) 2001-10-10 2003-07-17 Defeo-Jones Deborah Conjugates useful in the treatment of prostate cancer
US20040058857A1 (en) 2001-11-29 2004-03-25 Siu-Long Yao Method of treating cancer
US20070031438A1 (en) 2001-12-10 2007-02-08 Junghans Richard P Antibodies as chimeric effector cell receptors against tumor antigens
WO2003060074A2 (en) 2001-12-21 2003-07-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Novel metastasis suppressor gene on human chromosome 8
DK1472541T3 (da) 2002-01-10 2010-01-25 Univ Johns Hopkins Afbildningsmidler og metoder til at afbilde NAALADase og PSMA
CN1646147A (zh) 2002-02-06 2005-07-27 约翰斯霍普金斯医学院 用于将系统性免疫应答靶向于特定器官或组织的方法和组合物
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US8491896B2 (en) 2002-06-14 2013-07-23 Immunomedics, Inc. Anti-pancreatic cancer antibodies
US7344700B2 (en) 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
US9745380B2 (en) 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
WO2003074566A2 (en) 2002-03-01 2003-09-12 Immunomedics, Inc. Rs7 antibodies
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20170281791A1 (en) 2002-03-01 2017-10-05 Immunomedics, Inc. Anti-trop-2 antibody-drug conjugates and uses thereof
JP2005518822A (ja) 2002-03-07 2005-06-30 ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン 後生的に沈黙化されたガン関連遺伝子のゲノムスクリーニング
US7534580B2 (en) 2002-05-01 2009-05-19 Ambrilia Biopharma Inc. PSP94 diagnostic reagents and assays
NZ536467A (en) 2002-05-06 2006-11-30 Endocyte Inc Vitamin-targeted imaging agents
US7910594B2 (en) 2002-05-15 2011-03-22 Endocyte, Inc. Vitamin-mitomycin conjugates
KR101143035B1 (ko) 2002-06-14 2012-05-08 이뮤노메딕스, 인코오포레이티드 단클론 항체 ｈＰＡＭ4
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
AR040956A1 (es) 2002-07-31 2005-04-27 Schering Ag Nuevos conjugados de efectores, procedimientos para su preparacion y su uso farmaceutico
WO2006028429A2 (en) 2002-08-05 2006-03-16 The Johns Hopkins University Peptides for targeting the prostate specific membrane antigen
US7662795B2 (en) 2002-08-08 2010-02-16 The Johns Hopkins University Enhancement of adenoviral oncolytic activity by modification of the E1A gene product
US8487128B2 (en) 2002-11-26 2013-07-16 Chs Pharma, Inc. Protection of normal cells
EP1572242B1 (en) 2002-12-13 2014-04-16 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US7875586B2 (en) 2002-12-20 2011-01-25 The Johns Hopkins University Treatment of metastatic colon cancer with b-subunit of shiga toxin
US7166691B2 (en) 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US20080008649A1 (en) * 2003-01-13 2008-01-10 Bracco Imaging S.P.A. Gastrin Releasing Peptide Compounds
EP2517729A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
CA2514419A1 (en) 2003-01-28 2004-08-12 Proscan Rx Pharma Inc. Prostate cancer diagnosis and treatment
EP1444990A1 (en) 2003-02-07 2004-08-11 Amersham plc Improved Radiometal Complex Compositions
WO2004072081A1 (en) 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
WO2004080412A2 (en) 2003-03-07 2004-09-23 The University Of Toledo Paclitaxel hybrid derivatives
US20070179100A1 (en) 2003-04-09 2007-08-02 Muthiah Manoharan Protected monomers
DK1620544T3 (en) 2003-04-17 2019-01-14 Alnylam Pharmaceuticals Inc MODIFIED iRNA AGENTS
WO2004096120A2 (en) 2003-05-01 2004-11-11 Nst Neurosurvival Technologies Ltd. Compounds that selectively bind to membranes of apoptotic cells
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7172751B2 (en) 2003-06-13 2007-02-06 Immunomedics, Inc. D-amino acid peptides
US7232805B2 (en) 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
US20050255042A1 (en) 2003-11-24 2005-11-17 The Regents Of The University Of California Office Of Technology Transfer, University Of California On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
FR2864546A1 (fr) 2003-12-24 2005-07-01 Assist Publ Hopitaux De Paris Methode d'identification et de preparation de lymphocytes t regulateurs/suppresseurs, compositions et utilisations
ES2328369T3 (es) 2004-01-12 2009-11-12 Applied Molecular Evolution, Inc. Variantes de la region fc.
WO2006075333A2 (en) 2005-01-13 2006-07-20 Spectrum Dynamics Llc Multi-dimensional image reconstruction and analysis for expert-system diagnosis
US8586932B2 (en) 2004-11-09 2013-11-19 Spectrum Dynamics Llc System and method for radioactive emission measurement
DE102004004787A1 (de) 2004-01-30 2005-08-18 Schering Ag Neue Effektor-Konjugate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
JP5064037B2 (ja) 2004-02-23 2012-10-31 ジェネンテック， インコーポレイテッド 複素環式自壊的リンカーおよび結合体
EP1610818A4 (en) 2004-03-03 2007-09-19 Millennium Pharm Inc MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF
WO2005085292A2 (fr) 2004-03-03 2005-09-15 Biomerieux Procede de detection de la forme libre activable du psa et son utilisation pour le diagnostic des pathologies benignes de la prostate et de l'adenocarcinome de la prostate
ES2311895T3 (es) 2004-03-15 2009-02-16 F. Hoffmann-La Roche Ag El uso de los peptidos tipo bnp y de los peptidos tipo anf para evaluar el riesgo de padecer una complicacion cardio-vascular como frecuencia de sobrecarga del volumen.
CA2606138A1 (en) 2004-04-19 2005-10-27 Proscan Rx Pharma Prostate cancer diagnosis and treatment
US20060105975A1 (en) 2004-04-19 2006-05-18 Shannon Pendergrast Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
MXPA06013413A (es) 2004-05-19 2007-01-23 Medarex Inc Enlazadores quimicos y conjugados de los mismos.
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
US20060148741A1 (en) 2004-07-26 2006-07-06 Government Of The Usa, Represented By The Secretary, Department Of Health And Human Services Metastasis suppressor gene on human chromosome 8 and its use in the diagnosis, prognosis and treatment of cancer
DK1776384T3 (da) 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT-Fc-REGIONER
US20060045883A1 (en) 2004-08-26 2006-03-02 Jeffrey Molldrem Anti-cancer vaccines
WO2006024160A1 (en) 2004-08-30 2006-03-09 Neuromed Pharmaceuticals Ltd. Urea derivatives as calcium channel blockers
US8194660B2 (en) 2004-09-09 2012-06-05 Amx Llc System, method, and computer-readable medium for dynamic device discovery for servers binding to multiple masters
US7713944B2 (en) 2004-10-13 2010-05-11 Isis Pharmaceuticals, Inc. Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cells
WO2006049891A1 (en) 2004-10-27 2006-05-11 Janssen Pharmaceutica N.V. Trisubstituted thiophenes as progesterone receptor modulators
US8000773B2 (en) 2004-11-09 2011-08-16 Spectrum Dynamics Llc Radioimaging
EP1827505A4 (en) 2004-11-09 2017-07-12 Biosensors International Group, Ltd. Radioimaging
US20060140871A1 (en) 2004-11-30 2006-06-29 Sillerud Laurel O Magnetic resonance imaging of prostate cancer
US7741510B2 (en) 2005-01-13 2010-06-22 E. I. Du Pont De Nemours And Company Rheology control agents
US20060155021A1 (en) 2005-01-13 2006-07-13 Lenges Christian P Coating compositions containing rheology control agents
AU2006210794A1 (en) 2005-02-01 2006-08-10 Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Biomarkers for tissue status
WO2006093991A1 (en) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
US20090105172A1 (en) 2005-03-07 2009-04-23 Diener John L Stabilized Aptamers to PSMA and Their Use as Prostate Cancer Therapeutics
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
KR101068612B1 (ko) 2005-05-24 2011-09-30 휴마시스 주식회사 유사구조 단백질 비율 측정을 이용한 진단장치
AU2006257664B2 (en) 2005-06-14 2013-01-10 Protox Therapeutics Incorporated Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
KR20080031296A (ko) 2005-06-20 2008-04-08 피에스엠에이 디벨롭먼트 캄파니, 엘엘씨 Ｐｓｍａ 항체-약물 접합체
US20070009434A1 (en) 2005-07-05 2007-01-11 Low Philip S Imaging and therapeutic method using monocytes
US20070010014A1 (en) 2005-07-06 2007-01-11 General Electric Company Compositions and methods for enhanced delivery to target sites
EP1909853B1 (en) 2005-07-19 2015-03-18 Biosensors International Group, Ltd. Imaging protocols
JP2009504786A (ja) 2005-08-19 2009-02-05 シーラス コーポレイション リステリア属誘導型免疫漸増および活性化、ならびにその使用方法
EP1948240A2 (en) 2005-08-19 2008-07-30 Endocyte, Inc. Ligand conjugates of vinca alkaloids, analogs and derivatives
WO2007022494A2 (en) 2005-08-19 2007-02-22 Endocyte, Inc. Multi-drug ligand conjugates
EP2015781A4 (en) 2005-09-12 2009-12-23 Univ Johns Hopkins COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
EP1957113A4 (en) 2005-11-21 2011-11-09 Medivas Llc POLYMER PARTICLES FOR THE OUTPUT OF MACROMOLECULES AND METHOD OF APPLICATION THEREFOR
CN104090095B (zh) 2005-11-23 2016-06-01 文塔纳医疗系统公司 分子缀合物
US8258256B2 (en) 2006-01-05 2012-09-04 The Johns Hopkins University Compositions and methods for the treatment of cancer
WO2007087131A2 (en) 2006-01-05 2007-08-02 The Johns Hopkins University Peptide prodrugs
US7635682B2 (en) 2006-01-06 2009-12-22 Genspera, Inc. Tumor activated prodrugs
JP2009525048A (ja) 2006-02-01 2009-07-09 ザ ジョンズ ホプキンス ユニバーシティー 腫瘍性障害または感染症に対する免疫学的予防法または免疫療法のためのポリペプチド−核酸複合体
CA2645809C (en) 2006-03-14 2015-05-26 Cancer Targeted Technology Llc Peptidomimetic inhibitors of psma, compounds comprising them, and methods of use
US8940871B2 (en) 2006-03-20 2015-01-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
US20070225213A1 (en) 2006-03-23 2007-09-27 Kosak Matthew K Nucleic acid carriers for delivery of therapeutic agents
EP2007435B1 (en) 2006-03-31 2019-12-18 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US20140314864A1 (en) 2006-03-31 2014-10-23 Massachusetts Institute Of Technology System for Targeted Delivery of Therapeutic Agents
US7842280B2 (en) 2006-09-06 2010-11-30 Case Western Reserve University Flexibly labeling peptides
JP2010509570A (ja) 2006-11-03 2010-03-25 パーデュー・リサーチ・ファウンデーション エクスビボフローサイトメトリーの方法および装置
ES2847275T3 (es) 2006-11-08 2021-08-02 Molecular Insight Pharm Inc Heterodímeros de ácido glutámico
US9387344B2 (en) 2006-11-21 2016-07-12 The Johns Hopkins University Methods for determining absorbed dose information
JP2010511713A (ja) 2006-12-05 2010-04-15 ランデック コーポレイション 薬物送達
US8507434B2 (en) 2007-01-03 2013-08-13 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
JP5388355B2 (ja) 2007-01-11 2014-01-15 イミューノメディクス、インコーポレイテッド タンパク質、ペプチドおよび他の分子の改善されたｆ−１８標識化のための方法および組成物
AU2007345648A1 (en) 2007-01-26 2008-08-07 City Of Hope Methods and compositions for the treatment of cancer or other diseases
WO2008098112A2 (en) 2007-02-07 2008-08-14 Purdue Research Foundation Positron emission tomography imaging method
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
NZ599239A (en) 2007-03-14 2013-10-25 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins
JP2010524856A (ja) 2007-04-10 2010-07-22 ザ・ジョンズ・ホプキンス・ユニバーシティー ウイルス関連腫瘍の画像化および治療
BRPI0812970A2 (pt) 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
EP2170075B1 (en) 2007-06-26 2014-12-03 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
GB0723246D0 (en) 2007-07-03 2008-01-09 Barton Michelle p53 modulator
EP2170946A2 (en) 2007-07-13 2010-04-07 The Johns Hopkins University B7-dc variants
RU2010107199A (ru) 2007-07-31 2011-09-10 Дзе Джонс Хопкинс Юниверсити (Us) Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений
US8013991B2 (en) 2007-08-08 2011-09-06 Chemimage Corporation Raman difference spectra based disease classification
PT2187965T (pt) 2007-08-17 2020-01-17 Purdue Research Foundation Conjugados ligando-ligante de ligação a psma e métodos para utilização
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
WO2009033161A1 (en) 2007-09-07 2009-03-12 The John Hopkins University Adenosine receptor agonists and antagonists to modulate t cell responses
DK2644594T3 (en) 2007-09-28 2017-10-02 Pfizer Cancer cell targeting using nanoparticles
CA2703491C (en) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysins and processes for preparing
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009070302A1 (en) 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
AU2008340354B2 (en) 2007-12-04 2014-04-17 Alnylam Pharmaceuticals, Inc. Folate-iRNA conjugates
US20090180951A1 (en) 2007-12-12 2009-07-16 Molecular Insight Pharmaceuticals, Inc. Inhibitors of integrin vla-4
CN102083427B (zh) 2008-01-09 2014-12-10 分子洞察制药公司 碳酸酐酶ix的抑制剂
US8565945B2 (en) 2008-01-17 2013-10-22 Lockheed Martin Corporation Method for managing vital train movements
EP2259836A2 (en) 2008-04-04 2010-12-15 Molecular Insight Pharmaceuticals, Inc. Radiolabeled treatment infusion system, apparatus, and methods of using the same
ITTO20080313A1 (it) 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
EP2990487A1 (en) 2008-05-08 2016-03-02 Asuragen, INC. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
RS54428B1 (en) 2008-05-13 2016-04-28 Yale University CHIMERIC SMALL MOLECULES FOR THE REGULATION OF ANTIBODY ANTIBODIES
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
KR101706178B1 (ko) 2008-06-16 2017-02-15 화이자 인코포레이티드 약물 부하된 중합체성 나노입자, 및 이의 제조 및 사용 방법
WO2010002418A2 (en) 2008-07-01 2010-01-07 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
LT2318366T (lt) 2008-08-01 2017-10-25 The Johns Hopkins University Psma surišantys agentai ir jų panaudojimas
WO2010019446A1 (en) 2008-08-09 2010-02-18 University Of Iowa Research Foundation Nucleic acid aptamers
WO2010019963A2 (en) 2008-08-15 2010-02-18 Georgetown University Na channels, disease, and related assays and compositions
ES2438495T3 (es) 2008-09-08 2014-01-17 Psma Development Company, L.L.C. Compuestos para exterminar células cancerosas que expresan PSMA, resistentes a taxano
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
WO2010033733A1 (en) 2008-09-17 2010-03-25 Endocyte, Inc. Folate receptor binding conjugates of antifolates
WO2010045598A2 (en) 2008-10-17 2010-04-22 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
WO2010065906A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer
CN102272101A (zh) 2008-12-05 2011-12-07 分子制药洞察公司 用于癌症治疗和成像的ca-ix特异性放射性药物
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
CA2749501C (en) 2009-02-13 2017-01-10 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
EP3495000A1 (en) 2009-02-17 2019-06-12 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
US20100260677A1 (en) 2009-03-02 2010-10-14 Massachusetts Institute Of Technology Methods and systems for treatment and/or diagnosis
US8772226B2 (en) 2009-03-17 2014-07-08 The Johns Hopkins University Methods and compositions for the detection of cancer
US10717750B2 (en) 2009-03-19 2020-07-21 The Johns Hopkins University 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents
EP4420730A3 (en) * 2009-03-19 2024-11-13 The Johns Hopkins University Psma-targeting compounds and uses thereof
US9757084B2 (en) 2011-12-22 2017-09-12 The Johns Hopkins University Method and system for administering radiopharmaceutical therapy (RPT)
US20120183847A1 (en) 2009-05-19 2012-07-19 Aic Blab Composite current collector and methods therefor
WO2010147965A2 (en) 2009-06-15 2010-12-23 Molecular Insight Pharmaceuticals, Inc. Process for production of heterodimers of glutamic acid
CN102549434A (zh) 2009-07-31 2012-07-04 恩多塞特公司 叶酸盐靶向的诊断和治疗
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
WO2011031517A1 (en) 2009-08-27 2011-03-17 Nuclea Biotechnologies, LLC Method and assay for determining fas expression
CN105085681B (zh) 2009-12-02 2018-12-28 伊麦吉纳博公司 靶向人前列腺特异性膜抗原的j591微抗体和双抗体
WO2011072218A2 (en) 2009-12-11 2011-06-16 Bind Biosciences Stable formulations for lyophilizing therapeutic particles
AU2011212813B2 (en) 2010-02-04 2014-10-23 Radius Health, Inc. Selective androgen receptor modulators
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US20120322741A1 (en) 2010-02-25 2012-12-20 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US8685416B2 (en) 2010-03-02 2014-04-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of cancer
JP2010159277A (ja) 2010-03-04 2010-07-22 Sumitomo Chemical Co Ltd 有害生物防除組成物及び有害生物の防除方法
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
US9006415B2 (en) 2010-04-06 2015-04-14 Massachusetts Institute Of Technology Targeted delivery of nucleic acids
ES2430567T3 (es) 2010-04-15 2013-11-21 Spirogen Sàrl Pirrolobenzodiacepinas y conjugados de las mismas
HUE029293T2 (hu) 2010-05-05 2017-02-28 Safety Syringes Inc Csavarvonal alakú tekercses biztonsági eszköz tûhöz
CN101863924B (zh) 2010-05-17 2012-06-27 北京师范大学 99mTc标记肼基烟酰胺基-二氧辛酰-叶酸配合物及制备方法
US20130302409A1 (en) 2010-07-16 2013-11-14 Yale University Methods and compositions for cancer immunotherapy
US9029340B2 (en) 2010-07-22 2015-05-12 The Johns Hopkins University Radiation sensitization agents for prostate cancer
WO2012033911A2 (en) 2010-09-08 2012-03-15 The Johns Hopkins University Polyionic papilloma virus-like particle (vlp) vaccines
KR101236142B1 (ko) 2010-09-30 2013-02-21 경북대학교 산학협력단 가돌리늄 착물을 함유하는 ｍｒｉ조영제
JP6275484B2 (ja) 2010-12-06 2018-02-07 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド Ｐｓｍａ標的化デンドリマー
US10029023B2 (en) 2011-03-31 2018-07-24 The Johns Hopkins University Theranostic imaging agents and methods of use
EA201391449A1 (ru) 2011-04-01 2014-03-31 Мемориал Слоан-Кеттеринг Кэнсер Сентер Антитела против пептидов цитозоля
US8921378B2 (en) 2011-04-21 2014-12-30 Orion Corporation Androgen receptor modulating carboxamides
US9180214B1 (en) 2011-04-22 2015-11-10 Stc.Unm Gonadotropin-releasing hormone receptor-targeting peptides and their use to treat and diagnose cancer
WO2012154511A2 (en) 2011-05-06 2012-11-15 The Johns Hopkins University Method and device for statistical tissue sampling using microdevices
WO2012166923A2 (en) 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
CN107325127B (zh) * 2011-06-15 2020-09-01 癌靶技术有限责任公司 螯合的psma抑制剂
AU2012294639B2 (en) * 2011-08-05 2017-10-26 Molecular Insight Pharmaceuticals, Inc. Radiolabeled prostate specific membrane antigen inhibitors
US10011632B2 (en) 2011-08-22 2018-07-03 Siemens Medical Solutions Usa, Inc. PSMA imaging agents
US9034318B2 (en) 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
WO2013060793A1 (en) * 2011-10-25 2013-05-02 Technische Universität München Bifunctional ligands for radiometals
WO2013070457A2 (en) 2011-11-01 2013-05-16 The Johns Hopkins University Method and device for endoscopic abrasion
EP2785712B1 (en) 2011-11-30 2019-05-01 The Johns Hopkins University Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof
CA2860504A1 (en) 2012-01-06 2013-07-11 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase ix
WO2013130776A1 (en) 2012-02-29 2013-09-06 Purdue Research Foundation Folate receptor alpha binding ligands
US9498546B2 (en) 2012-03-14 2016-11-22 The Johns Hopkins University Synthesis and application of novel imaging agents conjugated to DPA 713 analogs for imaging inflammation
US9556167B2 (en) 2012-05-02 2017-01-31 Yale University TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs)
WO2013185052A1 (en) 2012-06-08 2013-12-12 Aduro Biotech Compostions and methods for cancer immunotherapy
NZ704487A (en) 2012-07-27 2018-05-25 Aragon Pharmaceuticals Inc Methods and compositions for determining resistance to androgen receptor therapy
US20140107316A1 (en) 2012-10-16 2014-04-17 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
JP2015536323A (ja) 2012-10-16 2015-12-21 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 非天然アミノ酸を含む薬物送達結合体および使用方法
US20140113322A1 (en) 2012-10-22 2014-04-24 The Johns Hopkins University Supramolecular nanobeacon imaging agents as protease sensors
EP2911701A4 (en) 2012-10-23 2016-06-08 Univ Johns Hopkins Novel self-assembling drug amphiphiles and methods for synthesis and application
EA201890915A1 (ru) 2012-11-15 2018-09-28 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
US20140154702A1 (en) 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
KR102002826B1 (ko) 2012-12-04 2019-07-23 삼성전자 주식회사 저장 장치, 플래시 메모리 및 저장 장치의 동작 방법
WO2014096365A1 (en) 2012-12-21 2014-06-26 Spirogen Sàrl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
MX360098B (es) 2012-12-28 2018-10-22 Tarveda Therapeutics Inc Conjugados dirigidos encapsulados en partículas y sus formulaciones.
WO2014110372A1 (en) 2013-01-14 2014-07-17 Molecular Insight Pharmaceuticals Triazine based radiopharmaceuticals and radioimaging agents
US10207005B2 (en) 2013-02-15 2019-02-19 Case Western Reserve University Photodynamic therapy composition
EP2958596B1 (en) 2013-02-15 2019-12-04 Case Western Reserve University Psma ligands and uses thereof
US20140249315A1 (en) 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
US9255262B2 (en) 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
US9567402B2 (en) 2013-03-14 2017-02-14 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate and other cancer cells
US10434194B2 (en) 2013-06-20 2019-10-08 Case Western Reserve University PSMA targeted nanobubbles for diagnostic and therapeutic applications
EP3336103B1 (en) 2013-07-10 2021-03-17 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
JP5817799B2 (ja) 2013-10-10 2015-11-18 ダイキン工業株式会社 空気調和機
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10232058B2 (en) 2013-10-14 2019-03-19 The Johns Hopkins University Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy
US10406246B2 (en) 2013-10-17 2019-09-10 Deutsches Kresbsforschungszentrum Double-labeled probe for molecular imaging and use thereof
HRP20240398T1 (hr) * 2013-10-18 2024-06-07 Novartis Ag Označeni inhibitori prostata specifičnog membranskog antigena (psma), njihova upotreba kao sredstava za snimanje i farmaceutska sredstva za liječenje raka prostate
CA2927103A1 (en) 2013-10-18 2015-04-23 Molecular Insight Pharmaceuticals, Inc. Methods of using spect/ct analysis for staging cancer
US20150110814A1 (en) 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
ITAN20130219A1 (it) 2013-11-21 2015-05-22 Gianluca Valentini Farmaco anti-cancro, comprendente un radioisotopo del rame
JP2016538852A (ja) 2013-11-25 2016-12-15 オックスフォード バイオセラピューティックス リミテッドＯｘｆｏｒｄ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ がん治療のための抗体抗マトリプターゼ
US9346846B1 (en) 2013-12-02 2016-05-24 Yale University Anti-cancer compounds and methods for treating cancer
CN105828863B (zh) 2013-12-18 2020-06-09 皇家飞利浦有限公司 基于心脏或呼吸特性来增强睡眠慢波活动的系统和方法
US11124845B2 (en) 2014-03-18 2021-09-21 The Johns Hopkins University PSMA-based molecular-genetic reporter system
US10683272B2 (en) 2014-05-06 2020-06-16 The Johns Hopkins University Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy
EP2944635B1 (en) 2014-05-15 2018-11-28 Council of Scientific & Industrial Research Pyrazole linked benzimidazole conjugates and a process for preparation thereof
US9814759B2 (en) 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
CA2961575C (en) 2014-08-06 2023-09-19 The Johns Hopkins University Methods for treating inflammatory bowel disease using prostate specific membrane antigen (psma) inhibitors
SI3177632T1 (sl) 2014-08-06 2022-05-31 The Johns Hopkins University Predzdravilo inhibitorja za prostato specifičnega membranskega antigena
US10112974B2 (en) 2014-08-24 2018-10-30 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer
EP2993171A1 (en) 2014-09-04 2016-03-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18F-labeled PSMA-specific PET-tracers
EP3186393A4 (en) 2014-08-25 2018-01-10 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
WO2016040179A1 (en) 2014-09-08 2016-03-17 Molecular Insight Pharmaceuticals, Inc. Organ protection in psma-targeted radionuclide therapy of prostate cancer
EP3209336B1 (en) 2014-10-20 2019-12-11 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2016065142A2 (en) 2014-10-22 2016-04-28 The Johns Hopkins University New scaffolds and multifunctional intermediates for imaging psma and cancer therapy
US11033637B2 (en) 2014-11-21 2021-06-15 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
KR101698654B1 (ko) 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
WO2016115415A1 (en) 2015-01-16 2016-07-21 The Johns Hopkins University Albumin-proaerolysin prodrugs
WO2016115445A1 (en) 2015-01-16 2016-07-21 The Johns Hopkins University Synthetic enhancement of the t-cell armamentarium as an anti-cancer therapy
CA2982543A1 (en) 2015-04-13 2016-10-20 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
JP7114457B2 (ja) 2015-04-17 2022-08-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
US9808538B2 (en) 2015-09-09 2017-11-07 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
KR101639599B1 (ko) 2015-11-09 2016-07-14 서울대학교산학협력단 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물
FR3043970B1 (fr) 2015-11-25 2019-06-21 Medtech Sa Systeme mecanique de stabilisation au sol pour vehicules a roulettes
US10688200B2 (en) 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
ES2944610T3 (es) 2016-09-09 2023-06-22 On Target Laboratories Llc Colorantes NIR dirigidos a PSMA y sus usos
WO2018191376A2 (en) 2017-04-11 2018-10-18 The Johns Hopkins University Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy
BR112020011789A2 (pt) 2017-12-13 2020-11-24 Sciencons AS complexo que compreende um composto de alvejamento de psma ligado a um radionuclídeo de chumbo ou tório
IL276653B2 (en) 2018-02-22 2024-11-01 The Us Secretary Department Of Health And Human Services Chemical Conjugates of Evans Blue History and Their Use as Radiotherapy and Imaging Agents for Prostate Cancer Targeting
CN112351820B (zh) 2018-06-21 2024-10-11 瑞泽恩制药公司 双特异性抗psma x抗cd28抗体及其用途

Also Published As

Publication number Publication date
ES2977715T3 (es) 2024-08-29
CN105636924A (zh) 2016-06-01
AU2014336638B2 (en) 2017-10-19
ZA201603380B (en) 2020-05-27
IL245113B (en) 2020-08-31
AU2018200419A1 (en) 2018-02-08
GEP20237497B (en) 2023-04-10
HRP20240398T1 (hr) 2024-06-07
MY194484A (en) 2022-11-30
ZA201907607B (en) 2021-05-26
CL2016000883A1 (es) 2016-10-21
JP7194161B2 (ja) 2022-12-21
US11951190B2 (en) 2024-04-09
PE20211760A1 (es) 2021-09-07
JP2024028742A (ja) 2024-03-05
KR20210013350A (ko) 2021-02-03
EA201690495A1 (ru) 2016-10-31
CN105636924B (zh) 2018-08-07
PL4095130T3 (pl) 2024-06-10
EP3495355A1 (en) 2019-06-12
CN109053616A (zh) 2018-12-21
CA2924360A1 (en) 2015-04-23
EP4374924A2 (en) 2024-05-29
JP6556805B2 (ja) 2019-08-07
JP7036774B2 (ja) 2022-03-15
US10398791B2 (en) 2019-09-03
KR20160063398A (ko) 2016-06-03
HK1221711A1 (zh) 2017-06-09
IL268974A (en) 2019-10-31
EP4095130B1 (en) 2024-01-31
EP3415489A1 (en) 2018-12-19
KR102210931B1 (ko) 2021-02-02
AU2018200419B2 (en) 2019-11-14
US10471160B2 (en) 2019-11-12
US20190008988A1 (en) 2019-01-10
NL301281I2 (nl) 2024-08-01
NZ718812A (en) 2017-08-25
JP2022159345A (ja) 2022-10-17
WO2015055318A1 (en) 2015-04-23
EP4095130A1 (en) 2022-11-30
PE20160678A1 (es) 2016-08-06
US20210283279A1 (en) 2021-09-16
JP2016535013A (ja) 2016-11-10
MX2021008977A (es) 2021-09-08
JP2018058847A (ja) 2018-04-12
JP2019218351A (ja) 2019-12-26
CA2924360C (en) 2022-04-26
US20190336622A1 (en) 2019-11-07
US20240350680A1 (en) 2024-10-24
US20190060491A1 (en) 2019-02-28
PH12016500656B1 (en) 2016-06-13
DK4095130T3 (da) 2024-04-22
FIC20240024I1 (fi) 2024-06-28
FR24C1028I1 (fr) 2024-08-30
US11931430B2 (en) 2024-03-19
DE202014011593U1 (de) 2023-08-23
EP3038996A1 (en) 2016-07-06
US20190374660A1 (en) 2019-12-12
US11045564B2 (en) 2021-06-29
TN2016000137A1 (en) 2017-10-06
US20210177996A1 (en) 2021-06-17
RS65324B1 (sr) 2024-04-30
DE202014011600U1 (de) 2023-05-31
SG11201602249RA (en) 2016-05-30
SA516370842B1 (ar) 2020-06-07
HUS2400024I1 (hu) 2024-08-28
EP4374924A3 (en) 2024-08-07
CN109053616B (zh) 2022-08-19
JP7393485B2 (ja) 2023-12-06
SI4095130T1 (sl) 2024-05-31
PH12016500656A1 (en) 2016-06-13
EP3456700A1 (en) 2019-03-20
GEP20237496B (en) 2023-04-10
GEP20217330B (en) 2021-12-10
EP3038996B1 (en) 2022-06-15
KR20190016133A (ko) 2019-02-15
JP6901451B2 (ja) 2021-07-14
FI4095130T3 (fi) 2024-04-25
KR101947053B1 (ko) 2019-02-12
MX2021008976A (es) 2021-08-18
AU2014336638A1 (en) 2016-04-14
AU2014336638C1 (en) 2020-09-17
AU2020201086A1 (en) 2020-03-05
US20160228587A1 (en) 2016-08-11
AU2020201086B2 (en) 2021-07-08
JP2019011368A (ja) 2019-01-24
LT4095130T (lt) 2024-04-25
GEP20237479B (en) 2023-03-27
MY188934A (en) 2022-01-13
MX2016005013A (es) 2017-02-28
JP2021059557A (ja) 2021-04-15
KR102282378B1 (ko) 2021-07-27
EA037778B1 (ru) 2021-05-20
IL245113A0 (en) 2016-06-30
IL268974B (en) 2020-08-31

Similar Documents

Publication Publication Date Title
HUS2400024I1 (hu) A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére
PT4095130T (pt) Inibidores marcados do antígeno de membrana específico da próstata (psma), seu uso como agentes de imagem e agentes farmacêuticos para o tratamento do cancro da próstata
HK1255215A1 (zh) 用於成像和治療的尿素基前列腺特異性膜抗原(psma)抑制劑
HK1225998A1 (zh) 用於癌症治療的包含抗ceacam1抗體和抗pd抗體的組合物
SG2014008304A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
EP3033079A4 (en) Methods for the treatment of her2 amplified cancer
IL258378B (en) Inhibitors of 18f-labeled prostate-specific membrane antigen and their use as imaging agents for prostate cancer
EP3044197A4 (en) Halogenated compounds for cancer imaging and treatment and methods for their use
HK1222331A1 (zh) 修飾的繆勒抑制物質 蛋白及其用於疾病治療的用途
PT3089749T (pt) Preparações combinadas para o tratamento de cancro
HK1222548A1 (zh) 治療惡性腫瘤的藥物組合
PT2984108T (pt) Anticorpos anti-s100a7 para o tratamento e diagnóstico de cancro
EP2879705A4 (en) PEPTIDE VACCINES BASED ON THE EGFRVIII SEQUENCE FOR THE TREATMENT OF TUMORS
PT3356385T (pt) Inibidores etiquetados com 18f de antigénio de membrana específico de próstata (psma) e utilização dos mesmos como agentes de imagiologia para o cancro da próstata
IL232339A0 (en) 32rf10c antibodies, and their uses for cancer treatment
AU2013904239A0 (en) Pharmaceutical combinations for the treatment of cancer